Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Saiko nasal spray is a botanical therapeutic candidate derived from the *Bupleurum* plant (known as Saiko in Japanese and Chaihu in Chinese), developed by Fudan University. It is formulated for intranasal administration to treat fever and symptoms associated with acute upper respiratory tract infections. The extract contains active compounds such as saikosaponins, which are traditionally recognized for their antipyretic, anti-inflammatory, and immunomodulatory effects. A Phase 1 clinical trial (CTR20131363) was conducted in China to assess the safety, tolerability, and human dosage of the spray in healthy adult volunteers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Saiko nasal spray.